Cite

    C. Cerchione et al.. “High‐dose bendamustine plus brentuximab combination is effective and has a favourable toxicity profile in the treatment of refractory and relapsed Hodgkin lymphoma.” Hematological oncology, vol. 35, n.d., pp. 317–318. http://access.bl.uk/ark:/81055/vdc_100047414719.0x000031